Diagnosis for the patients with neuroendocrine tumor by 111In-DTPA-octreotide

Diagnosis for the patients with neuroendocrine tumor by 111In-DTPA-octreotide - Diagnosis of NET by OctreoScan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010183

Enrollment

Registered

2013-03-06

Start date

2013-03-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroendocrine tumors

Interventions

Study above the practical mediacal treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with primary or metastatic neuroendocrine tumor by other imaging modalities

Exclusion criteria

Exclusion criteria: The patients didn't consent about this study

Design outcomes

Primary

Measure	Time frame
sensitivity, specificity, and accuracy about the diagnosis of neuroendocrine tumor by 111In-DTPA-octreotide	—

Countries

Japan

Contacts

Public ContactKobayashi Noritoshi

Yokohama City University Hospital Clinical Oncology

norikoba@yokohama-cu.ac.jp+81-045-787-2623

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026